25+ year veteran to lead company’s commercial strategy and operations
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Counsyl is pleased to announce the appointment of Noah Nasser as Chief Commercial Officer. Since joining Counsyl in October 2016, Nasser has played a pivotal role in driving the sales strategy for Counsyl, bringing the company’s suite of genetic screening products and services to women’s health clinics nationwide. Nasser will now oversee the commercial function for Counsyl, which includes commercial strategy and operations, sales, marketing, market intelligence, and customer service.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171204005225/en/
Counsyl Appoints Noah Nasser as Chief Commercial Officer (Photo: Business Wire)
“I’m impressed with Noah’s commercial leadership and his intuition for what physicians and patients need,” said Ramji Srinivasan, co-founder and chief executive officer of Counsyl. “I’m confident Noah is the best fit to lead our commercial organization and will be crucial in educating women’s health providers and their patients in making critical, timely health decisions.”
With more than 25 years of experience in life sciences and diagnostics, Nasser fosters a deep understanding of clinician’s needs and how to connect them with the right products. Nasser joined Counsyl from San Diego-based biotechnology company AltheaDx where he served as senior vice president of sales. Prior to AltheaDx, Nasser was the vice president of global sales and market development at Verinata Health, where he led his team through the company's acquisition by Illumina in 2013.
“It’s an honor to take on this new role as we continue to build upon the successes and learnings from the last decade,” said Noah Nasser, chief commercial officer of Counsyl. “We have built a strong team and are proud of our leadership position in expanded carrier screening and remain focused on increasing market share of our best in class, non-invasive prenatal screening and hereditary cancer screening products. Counsyl’s growth prospects are strong, as is our continuing commitment to the introduction of industry leading products and workflow solutions for our providers and patients.”
Since the company’s founding in 2007, Counsyl has championed advances in genetic screening for women and their families and has screened more than 850,000 patients, served more than 17,000 health care providers, and provided more than 60,000 genetic counseling sessions.
Counsyl’s suite of products includes:
- Counsyl Foresight™ Carrier Screen: Identifies carrier status of couples to determine risk of hereditary conditions.
- Counsyl Prelude™ Prenatal Screen: As early as the tenth week of pregnancy, this non-invasive screening detects a fetus’ risk for chromosomal conditions such as Down syndrome.
- Counsyl Reliant™ Cancer Screen: Analyzes genes associated with an increased risk of 10 common cancers, including breast, ovarian, and pancreatic cancer.
- Counsyl Complete™: Our complete practice workflow solution, including pre-test education, billing support, clear results reporting, and on-demand genetic counseling.
Counsyl is committed to improving lives by providing actionable information that guides women and their families in making critical and timely health decisions. Whether it’s starting a family or evaluating risk for cancer, Counsyl's genetic screens provide patients with early awareness about genetic conditions, so they can live informed and prepare for the future. Counsyl has screened more than 850,000 patients and served more than 17,000 healthcare professionals. For more information, visit www.counsyl.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171204005225/en/
Donelle M. Gregory